Dataset Information

Citalopram in the treatment of elderly chronic heart failure combined with depression: A systematic review and meta-analysis.

ABSTRACT:

Background

Depression is an independent factor to predict the hospitalization and mortality in the chronic HF patients. Citalopram is known as an effective drug for depression treatment. Currently, there is no specific recommendation in the HF guidelines for the treatment of psychological comorbidity. In recent years, many studies have shown that the citalopram may be safe in treating of chronic HF with depression.

Objective

To evaluate the efficacy and safety of the citalopram in the treatment of elderly chronic HF combined with depression.

Methods

PubMed, EMBASE, Cochrane, Web of Science, CNKI, VIP, CBM, and Wanfang were searched from their inception to May 2022. In the treatment of elderly chronic HF combined with depression, randomized controlled studies of the citalopram were included. Independent screening and extraction of data information were conducted by two researchers, and the quality was assessed by the Cochrane bias risk assessment tool. Review manager 5.4.1 was employed for statistical analysis.

Results

The results of meta-analysis prove that the citalopram treatment for depressed patients with chronic HF has a benefit for HAMD-24 (MD: -8.51, 95% CI: -10.15 to -6.88) and LVEF (MD: 2.42, 95% CI: 0.51 to 4.33). Moreover, the score of GDS decreases, and NT-proBNP (MD: -537.78, 95% CI: -718.03 to -357.54) is improved. However, the comparison with the control group indicates that there is no good effect on HAMD-17 (MD: -5.14, 95% CI: -11.60 to 1.32), MADRS (MD: -1.57, 95% CI: -3.47 to 0.32) and LVEDD (MD: -1.45, 95% CI: -3.65 to -0.76). No obvious adverse drug reactions were observed.

Conclusion

Citalopram treatment for depressed patients with chronic HF has a positive effect on LVEF and NT-proBNP. It can alleviate HAMD-24 and GDS, but the relative benefits for LVEDD, HAMD-17 and MADRS still need to be verified.Systematic Review Registration: PROSPERO [CRD42021289917].

SUBMITTER: Yan L

PROVIDER: S-EPMC9933506 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Citalopram in the treatment of elderly chronic heart failure combined with depression: A systematic review and meta-analysis.

Yan Longmei L Ai Yuzhen Y Xing Yaxuan Y Wang Biqing B Gao Anran A Xu Qiwu Q Li Hongzheng H Chen Keji K Zhang Jingchun J

Frontiers in cardiovascular medicine 20230201

<h4>Background</h4>Depression is an independent factor to predict the hospitalization and mortality in the chronic HF patients. Citalopram is known as an effective drug for depression treatment. Currently, there is no specific recommendation in the HF guidelines for the treatment of psychological comorbidity. In recent years, many studies have shown that the citalopram may be safe in treating of chronic HF with depression.<h4>Objective</h4>To evaluate the efficacy and safety of the citalopram in ...[more]

PMID: 36818339

Similar Datasets

Project description:BackgroundQiliqiangxin (QLQX) capsules are a commonly used proprietary Chinese medicine for the adjuvant treatment of chronic heart failure (CHF) in China. In recent years, several randomized controlled trials (RCTs) have reported on the efficacy and safety of QLQX combined with sacubitril/valsartan for CHF.ObjectiveThe purpose of this study was to systematically analyze the clinical efficacy and safety of QLQX combined with sacubitril/valsartan in the management of CHF and to provide clinicians as well as scientists with optimal evidence-based medical evidence.MethodsWe searched RCTs to evaluate the efficacy and safety of QLQX combined with sacubitril/valsartan in the treatment of CHF in the Wanfang Database, China National Knowledge Infrastructure, China Science and Technology Journal Database, PubMed, Embase, and Cochrane Library databases from their inception until January 8, 2022. RCTs on QLQX in combination with sacubitril/valsartan for CHF were included. The outcome measures considered were total effective rate, left ventricular ejection fraction (LVEF), left ventricular end-diastolic dimension (LVEDD), 6-minute walking distance (6-MWD), and adverse events. The quality of the included RCTs was assessed thereafter using the Cochrane risk of bias tool. RevMan 5.3 software was used to conduct the meta-analysis.ResultsThe meta-analysis included 17 trials involving 1427 CHF patients. The results indicated that with sacubitril/valsartan administration combined with QLQX treatment, the total effective rate (relative risk (RR) = 1.24; 95% confidence interval (CI) (1.17, 1.31); p < 0.01), LVEF (mean difference (MD) = 6.20; 95% CI (5.36, 7.05; p < 0.01)), and 6-MWD (MD = 55.87; 95% CI (40.66, 71.09); p < 0.01) of CHF patients were significantly increased, and the LVEDD value of CHF patients was noted to be significantly reduced (MD = -3.98; 95% CI (-4.47, -3.48); p < 0.01). Moreover, there was no increase in the number of adverse events during treatment (RR = 0.67; 95% CI (0.33, 1.34); p < 0.01).ConclusionsThis study indicated that in CHF patients, on the basis of sacubitril/valsartan treatment, combination with QLQX can potentially enhance the total effective rate, improve LVEF and 6-MWD, and reduce LVEDD values, with good safety. However, considering the poor quality of the included studies, a multicenter, randomized, double-blind controlled study is needed for further confirmation.

Project description:BackgroundThe efficacy of statin therapy in patients with established chronic heart failure (CHF) is a subject of much debate.Methods and findingsWe conducted three systematic literature searches to assess the evidence supporting the prescription of statins in CHF. First, we investigated the participation of CHF patients in randomized placebo-controlled clinical trials designed to evaluate the efficacy of statins in reducing major cardiovascular events and mortality. Second, we assessed the association between serum cholesterol and outcome in CHF. Finally, we evaluated the ability of statin treatment to modify surrogate endpoint parameters in CHF. Using validated search strategies, we systematically searched PubMed for our three queries. In addition, we searched the reference lists from eligible studies, used the "see related articles" feature for key publications in PubMed, consulted the Cochrane Library, and searched the ISI Web of Knowledge for papers citing key publications. Search 1 resulted in the retrieval of 47 placebo-controlled clinical statin trials involving more than 100,000 patients. CHF patients had, however, been systematically excluded from these trials. Search 2 resulted in the retrieval of eight studies assessing the relationship between cholesterol levels and outcome in CHF patients. Lower serum cholesterol was consistently associated with increased mortality. Search 3 resulted in the retrieval of 18 studies on the efficacy of statin treatment in CHF. On the whole, these studies reported favorable outcomes for almost all surrogate endpoints.ConclusionsSince CHF patients have been systematically excluded from randomized, controlled clinical cholesterol-lowering trials, the effect of statin therapy in these patients remains to be established. Currently, two large, randomized, placebo-controlled statin trials are under way to evaluate the efficacy of statin treatment in terms of reducing clinical endpoints in CHF patients in particular.

Project description:BackgroundDengzhan Shengmai Capsule (DZSMC) is a potential treatment for chronic heart failure (CHF). However, its specific benefits in the treatment of CHF remain unclear.MethodsRelated randomized controlled trials were searched in eight databases up to January 28, 2025, and included studies were determined according to the inclusion criteria. Subsequently, the basic characteristics and data from these studies were recorded using Excel 2010. Outcome-related data were subsequently imported into Revman 5.3 for meta-analysis.ResultsFifteen randomized controlled trials with 1606 patients were included in this meta-analysis. The results showed that compared to conventional treatment group, DZSMC combination group significantly improved the clinical effective rate [RR = 1.21, 95% CI (1.16,1.26), P < 0.00001], brain natriuretic peptide (BNP) [MD = -112.60, 95%CI (-212.23, -12.96), P = 0.03], N-terminal pro-B-type natriuretic peptide (NT-proBNP) [MD = -88.27, 95%CI (-108.11, -68.42), P < 0.00001], left ventricular ejection fraction (LVEF) [MD = 6.42, 95% CI (5.57, 7.27), P < 0.00001], left ventricular end-diastolic diameter (LVEDD) [MD = -5.72, 95% CI (-7.56, -3.87), P < 0.00001], left ventricular end-systolic diameter (LVESD) [MD = -5.33, 95% CI (-7.41, -3.26), P < 0.00001], left ventricular end-systolic volume (LVESV) [MD = -20.71, 95% CI (-34.59, -6.82), P = 0.003], and 6 min walk test [MD = 51.90, 95%CI (19.08, 84.72), P = 0.002], while adverse events had no significant difference [RR = 0.70, 95%CI (0.42, 1.17), P = 0.17]. Funnel plots indicated no publication bias for BNP, NT-proBNP, LVEF, and LVESD, while potential bias was observed for other outcomes.ConclusionDZSMC effectively improves clinical symptoms, cardiac function, and ventricular remodeling in CHF patients, with good safety, making it a potential adjuvant therapy for CHF. However, further research is needed to explore the long-term safety of DZSMC in order to enrich clinical evidence.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024507368, PROSPERO [CRD42024507368].

Dataset Information

Citalopram in the treatment of elderly chronic heart failure combined with depression: A systematic review and meta-analysis.

Background

Objective

Methods

Results

Conclusion

Publications

Citalopram in the treatment of elderly chronic heart failure combined with depression: A systematic review and meta-analysis.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets